Clinical Trial

Prostate Cancer Screening: a Pilot Study

Study acronym: ProScreenMRI
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Prostate Cancer (PCa) is the second most frequently diagnosed tumour and the third most lethal among men in Europe. The lack of precise tools and examinations to precisely diagnose PCa has caused overtreatment of indolent and low-aggressive PCa, while in some other cases, with aggressive disease, diagnosis and treatment are dangerously delayed because cancer could be potentially missed. The present trial aims to study a new pathway to early diagnose PCa with Magnetic Resonance Imaging (MRI) to identify men who will not need treatment and those who will benefit from radical treatment, thus improving disease control and quality of life.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-01-25; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-04-01
Status change: Enrolling by Invitation → Not Yet Recruiting 2024-03-29
Trial Details
NCT Number NCT06238661
Lead Sponsor Fondazione del Piemonte per l'Oncologia
Collaborators: San Luigi Gonzaga Hospital, Epidemiology and Screening Unit - CPO, Turin, Italy, ASL TO5
Conditions Prostate Cancer
Enrollment 4,500 participants
Start Date 2025-02-17
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-05